Long Term Health Spending Alongside Population Aging in N11 Emerging Nations

The rise of “emerging markets” is one of the key changes that is causing the global economic situation to unravel. The Next Eleven (Next-11) countries are known as the second-tier group of “emerging economies” behind the BRICS. Regardless of their diverse socio-geographical characteristics, the Next-11 countries have similarities pointing out to their high economic potential. The paper presents long-term differentials of accelerated population aging and corresponding health expenditure in the Next-11 nations from 1995 to 2013. An increase in the proportion of the elderly population, coupled with falling fertility rates, led the Next-11 countries to increase health care expenditures. Total health spending, expressed as a percentage of gross domestic products, gives clear evidence of growth. Private expenditure on health has been undergoing constant increases in recent years, driven primarily by out-of-pocket spending. Regardless of different health care financing mechanisms, all Next-11 health systems appear to withstand a heavy burden of an aging population, threatening their fiscal sustainability in the upcoming decades.

[1]  M. Szyszkowicz,et al.  Life expectancy , 2019, OECD Pensions at a Glance.

[2]  M. Jakovljevic,et al.  Life expectancy and health expenditure evolution in Eastern Europe—DiD and DEA analysis , 2016, Expert review of pharmacoeconomics & outcomes research.

[3]  M. Jakovljevic,et al.  Growth of Global Health Spending Share in Low and Middle Income Countries , 2016, Front. Pharmacol..

[4]  M. Jakovljevic.  Comparison of historical medical spending patterns among the BRICS and G7 , 2016, Journal of medical economics.

[5]  M. Jakovljevic.  The aging of Europe. The unexplored potential , 2015 .

[6]  M. Jakovljevic,et al.  Population Aging from 1950 to 2010 in Seventeen Transitional Countries in the Wider Region of South Eastern Europe , 2015, South Eastern European Journal of Public Health.

[7]  M. Jakovljevic.  BRIC’s Growing Share of Global Health Spending and Their Diverging Pathways , 2015, Front. Public Health.

[8]  N. Maniadakis,et al.  Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece , 2015, ClinicoEconomics and outcomes research : CEOR.

[9]  A. Dagović,et al.  Radiation therapy remains the key cost driver of oncology inpatient treatment , 2015, Journal of medical economics.

[10]  M. Jakovljevic,et al.  Health Financing Constrained by Population Aging - An Opportunity to Learn from Japanese Experience / Finansiranje Zdravstvene Zaštite U Uslovima Starenja Popualcije - Prilika Da Učimo Na Japanskom Iskustvu , 2014 .

[11]  A. Kesselheim,et al.  High-cost generic drugs--implications for patients and policymakers. , 2014, The New England journal of medicine.

[12]  F. Lichtenberg,et al.  The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010. , 2014, Health policy.

[13]  M. Neovius,et al.  Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial , 2014, Annals of the rheumatic diseases.

[14]  M. Jakovljevic.  Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market , 2014 .

[15]  M. Jakovljevic,et al.  Contemporary generic market in Japan – key conditions to successful evolution , 2014, Expert review of pharmacoeconomics & outcomes research.

[16]  A. Shaughnessy.  Monoclonal antibodies: magic bullets with a hefty price tag , 2012, BMJ : British Medical Journal.

[17]  S. Feldman,et al.  Economic evaluation of systemic therapies for moderate to severe psoriasis , 2009, The British journal of dermatology.

[18]  W. Sanderson,et al.  The coming acceleration of global population ageing , 2008, Nature.

[19]  D. Gerber,et al.  Targeted therapies: a new generation of cancer treatments. , 2008, American family physician.

[20]  S. Gress.  Private health insurance in Germany: consequences of a dual system. , 2007, Healthcare policy = Politiques de sante.

[21]  Joaquim Oliveira Martins,et al.  The Drivers of Public Expenditure on Health and Long-Term Care: An Integrated Approach , 2006 .

[22]  D. Weil.  Population Aging , 2006 .

[23]  S. Gress.  The Role of Private Health Insurance in Social Health Insurance Countries – Implications for Canada , 2005 .

[24]  Deborah Schrag,et al.  The price tag on progress--chemotherapy for colorectal cancer. , 2004, The New England journal of medicine.

[25]  D N Mendelson,et al.  The effects of aging and population growth on health care costs. , 1993, Health affairs.

[26]  Bridget Martin,et al.  Countries , 2019, Survival or Extinction?.

[27]  M. Jakovljevic,et al.  Health Care Financing and Affordability in the Emerging Global Markets , 2016 .

[28]  M. Jakovljevic.  Targeted immunotherapies overtaking emerging oncology market value based growth. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[29]  Mihajlo B. Jakovljević,et al.  10.5937/mckg48-5071 = Recent developments in the world's leading generic markets , 2014 .

[30]  C. J. McGrath,et al.  The Effect , 2012 .

[31]  N. Shah,et al.  Impact of new drugs and biologics on colorectal cancer treatment and costs. , 2011, The American journal of managed care.

[32]  Organización Mundial de la Salud.  Global Health and Aging , 2011 .

[33]  Kowal Pr,et al.  Population aging in Sub-Saharan Africa: demographic dimensions 2006. , 2007 .

[34]  F. Colombo,et al.  Private Health Insurance in OECD Countries: The Benefits and Costs for Individuals and Health Systems , 2004 .

[35]  Deborah Carr,et al.  America's Aging Population: Trends and Uncertainties , 1996 .

[36]  Seiritsu Ogura.  The Cost of Aging: Public Finance Perspectives for Japan , 1994 .

[37]  Private Health Insurance in the U.K. , 1957, Canadian Medical Association journal.